Statins, the widely used class of drugs for cholesterol management, are now showing promising results in slowing smoking-induced lung damage. In a new study presented at CHEST 2006, the 72nd annual international scientific assembly of the American College of Chest Physicians (ACCP), current and former smokers who used statins had lower lung function decline than those not using statins, regardless of whether patients continued or stopped smoking.
"Until now, no medication has shown to slow smoking-induced lung damage," said Walid G. Younis, MD, University of Oklahoma Medical Center, Oklahoma City, OK. "Our study is the first to show that statins may decrease the decline in lung function in smokers and former smokers, and, therefore, prevent millions from developing debilitating diseases that could eventually lead to death."
Younis and colleagues from the University of Oklahoma Medical Center compared the effects of statins on the management of 182 current smokers and 303 former smokers, with a mean age 66.1 ± 2.1 years, seen at the Oklahoma City Veterans Hospital. Patients had at least two pulmonary function tests, with the time between the first and the last test being 2.7 ± 1.6 years. Patients were categorized by initial level of lung impairment, with 319 having obstructive lung disease, 99 having restrictive lung disease, and 67 patients having normal lung function. Of the patients, 238 were on statin for an average of 2.7 ± 1.8 years, while the remaining patients did not receive statins (control group).
Over the study follow-up period, the decline in FEV1 was 12.8 percent in the control group and 2.5 percent in the statin group. The decline in FVC was 10.3 percent in the control and 1.3 percent in the statin group. Both differences were highly significant. This beneficial effect of statin remained significant, irrespective of the type of lung disease and regardless of whether the patient continued or stopped smoking. Furthermore, statin use in patients with obstructive lung disease led to a 35 percent decline in the rate of respiratory-related emergency department visits and hospitalizations.
Researchers note that it is not known whether decreasing the rate of decline in lung function or whether preventing emphysema, an independent risk factor of lung cancer, could translate into a reduction of lung cancer.
"It is conceivable that long-term statin therapy could be used in smokers and former smokers to prevent and slow the progression of lung diseases," said Dr. Younis. "Even though statins may help with lung function, they have no effect on preventing a patient from the major smoking-related killer, which is lung cancer. Therefore, smokers should never lose their incentive to quit smoking."
"Smoking is the number one cause of lung cancer and chronic lung diseases in the world. Although statins may reduce the incidence of lung damage in smokers, patients must still be urged to stop smoking as the best way to maintain and improve their health," said Mark J. Rosen, MD, FCCP, President of the American College of Chest Physicians.
Jennifer Stawarz | EurekAlert!
Skin patch dissolves 'love handles' in mice
18.09.2017 | Columbia University Medical Center
Medicine of the future: New microchip technology could be used to track 'smart pills'
13.09.2017 | California Institute of Technology
Using ultrafast flashes of laser and x-ray radiation, scientists at the Max Planck Institute of Quantum Optics (Garching, Germany) took snapshots of the briefest electron motion inside a solid material to date. The electron motion lasted only 750 billionths of the billionth of a second before it fainted, setting a new record of human capability to capture ultrafast processes inside solids!
When x-rays shine onto solid materials or large molecules, an electron is pushed away from its original place near the nucleus of the atom, leaving a hole...
For the first time, physicists have successfully imaged spiral magnetic ordering in a multiferroic material. These materials are considered highly promising candidates for future data storage media. The researchers were able to prove their findings using unique quantum sensors that were developed at Basel University and that can analyze electromagnetic fields on the nanometer scale. The results – obtained by scientists from the University of Basel’s Department of Physics, the Swiss Nanoscience Institute, the University of Montpellier and several laboratories from University Paris-Saclay – were recently published in the journal Nature.
Multiferroics are materials that simultaneously react to electric and magnetic fields. These two properties are rarely found together, and their combined...
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems Holding GmbH about commercial use of a multi-well tissue plate for automated and reliable tissue engineering & drug testing.
MBM ScienceBridge GmbH successfully negotiated a license agreement between University Medical Center Göttingen (UMG) and the biotech company Tissue Systems...
Pathogenic bacteria are becoming resistant to common antibiotics to an ever increasing degree. One of the most difficult germs is Pseudomonas aeruginosa, a...
Scientists from the MPI for Chemical Energy Conversion report in the first issue of the new journal JOULE.
Cell Press has just released the first issue of Joule, a new journal dedicated to sustainable energy research. In this issue James Birrell, Olaf Rüdiger,...
19.09.2017 | Event News
12.09.2017 | Event News
06.09.2017 | Event News
19.09.2017 | Event News
19.09.2017 | Physics and Astronomy
19.09.2017 | Power and Electrical Engineering